From 'Hard to Replicate' to 'Scalable': Chinese Biotech Juncell Therapeutics Is Restructuring the Industrial Logic of TIL Therapy

In the landscape of tumor immunotherapy, solid tumors have always been the most challenging stronghold to conquer.

Over the past decade,CAR-TThe success in the field of hematological tumors has greatly raised the market's expectations for cell therapy, but this model has not been smoothly replicated in the field of solid tumors. The high heterogeneity of the patient population, the complex tumor microenvironment, the strong immune suppression mechanisms, and the heavy reliance on safety and medical resources during the treatment process have long trapped cell therapy for solid tumors in "Popular but not commercially successful"The awkward situation."

It is against this backdrop that,TIL(Tumor-Infiltrating Lymphocytes) therapy is highly anticipated.TILCells are a composite arm derived from tumor tissue, associated with tumor cells.Rich Experience in Struggle, with a deep understanding of the tumor microenvironment, possesses a natural advantage in treating solid tumors. As production processes, lymphodepletion regimens, and immune support strategies continue to be optimized, this approach is becoming increasingly mature, drawing closer to the true industrialization window.

At this critical juncture, deeply cultivateTILJuncell Therapeutics Announces Launch After Years of Therapy DevelopmentIPO (Related Review:Juncell Therapeutics Files for Hong Kong IPO, Post-Money Valuation of RMB 2.137 Billion in the Last Round）In the eyes of the industry, this cannot be measured merely as an ordinary secondary market investment event; it is more like a pivotal moment concerning the industrialization of solid tumor cell therapy.KnockoutBattle：TILCan the therapy shift from being a "highly personalized and complex treatment" to an immunotherapy solution for solid tumors that is replicable, scalable, and affordable within a real-world healthcare system?

Where is the Breakthrough for TIL Therapy?

Globally,TILThe therapy is not a new technology. As early as the 1980s, American research institutions isolated TIL from melanoma patients' tumors and reinfused them after expansion with IL-2.

It can be said that even before the advent of immune checkpoint inhibitors, TIL therapy had already demonstrated clear anti-tumor activity in solid tumors such as melanoma, with some patients even achieving long-term remission or even clinical cure.

Although Lovance, a U.S.-based company, was the first to possess the relevant technology and initiate commercial development, its TIL therapy-related product did not receive FDA approval for marketing until 2024. This delay was not due to a single technological bottleneck but rather a combination of various factors.

First is safety and clinical threshold.TraditionalTILThe treatment regimen typically requires patients to undergo high-intensity lymphodepleting chemotherapy before cell infusion to eliminate the existing immune cells in the body, paving the way for the infused cells.TILCreate favorable conditions for cells; at the same time, high doses are requiredIL-2To maintain cell activity. This combination not only leads to a significant increase in medical costs but also places extremely high demands on the patient's physical condition, organ function, and the hospital's qualifications, resulting in a long hospitalization period.ICUOccupying, greatly limiting its clinical application.

Secondly, there is manufacturing complexity and cost structure.TraditionalTILCell production often relies on a feeder cell system, involving multiple process steps and high manual participation, making it difficult to achieve standardized scale-up; once gene modification is involved, viral vectors further drive up production and quality control costs. This makesTILThe therapy faces a situation where "the efficacy is fascinating, but the cost is prohibitive."

In the face of these throughoutTILTherapy from the clinical end to the manufacturing endChronic IllnessChronic Diseases: Juncell Therapeutics Rises to the Challenge, Entering This Field.

Juncell Therapeutics chooses one"The Strategy of 'Industry Logic First': How to Systematically Reduce Treatment Safety Risks, Manufacturing Costs, and Clinical Use Barriers Without Sacrificing Therapeutic Potential."

This strategy is first reflected in itsDeepTIL™ platform. ThroughTILReconstruction of Cell Enrichment and Expansion Processes: Juncell Therapeutics Maintains Cell Viability and Quantity While AvoidingTILCells' Response to High ConcentrationIL-2Generate dependency, thereby getting rid ofIL-2Dependence on supportive therapy. This change is not simply "removing a medication step," but rather aTILThe resolution of the most criticized safety issues of the therapy over a long period.

On this basis, Juncell Therapeutics further reduced the intensity of lymphodepletion, allowing patients to complete the treatment without entering a sterile isolation environment, and even explored the administration route in day-care wards. The industrial significance of this change lies in,It allowsTILThe therapy truly has the realistic potential to expand to more levels of hospitals and reach a broader patient population.

At the same time, through a non-trophoblast cell culture system and a non-viral vector technology route, Juncell Therapeutics has significantly compressed the cost structure in the production process. This"The technical trade-offs that act simultaneously on the clinical end and the manufacturing end" makeTILThe therapy is more accessible in the real world.

This also explains a real logic: in the field of cell therapy for solid tumors, it is not only necessary to"Remarkable efficacy," and it must address the issues of "whether patients can use it, whether hospitals dare to use it, and whether the payment system can sustain it."

From GC101 to Platform Layout

If the technology selection constitutes Juncell Therapeutics'...TILAnswer to industrial challenges, then its core productGC101, is the validation of this logic.

GC101The target isPD-1Advanced late-line melanoma patients for whom antibody therapy has failed have now entered a critical stage.IIIn the clinical stage, and is considered to be有望成为中国首个获批上市的TILTherapy.From the publicly disclosed clinical information, it shows that under the premise of its efficacy being no less than that of competing products, it significantly improves safety: no need for high-intensity lymphodepletion, no need forIL-2Injection, significantly improving the frequency, severity, and recovery time of adverse reactions, basically avoiding the impact on the treatment process.ICUResource dependency. What is particularly valuable is that the trials include cases with a huge tumor burden (exceeding18cm), and other refractory melanoma patients with multiple metastases achieving objective remission.

More importantly,GC101Has demonstrated therapeutic potential in pan-solid tumors. Except for melanoma,GC101It has demonstrated excellent efficacy in various types of solid tumors, including non-small cell lung cancer, cervical cancer, endometrial cancer, squamous cell carcinoma of the head and neck, as well as highly treatment-resistant pancreatic cancer and glioblastoma. In multiple cases, patients' tumors have been completely eradicated, with the longest tumor-free survival exceeding4Year. This providesGC101 TILThe application of the therapy in a broader range of solid tumors lays a solid foundation.

But the goal of Juncell Therapeutics is not limited to"Run out a product."

From the pipeline layout,GC101More like a "stepping stone," its true long-term value lies in supporting a sustainably expandable platform system.InGC101On the basis, Juncell Therapeutics has advancedGC203This non-viral vector gene modificationTILProduct. By introducing membrane-bound, self-aggregatingIL-7，GC203Attempt to EnhanceTILCells adapt within the body and remodel the tumor microenvironment, thereby further amplifying anti-tumor effects.GC203Based on this, it has also derived dual-gene modifications.GC301、GC304...and more, providing additional powerful tools for the treatment of solid tumors.

More forward-looking is based onRiverTIL™ Platform Development EndogenousTILWait for the next generation layout. The core idea of this direction is,OmissionTILLarge-scale ex vivo cell expansion steps, enablingTILSeed cells self-expand in vivo, thereby fundamentally shortening the treatment waiting time and further reducing production costs.

From an industry perspective, the potential and capability to move from a single product with a single indication to a single product with multiple indications, and then to multiple products with broader indications, determine whether a cell therapy company possesses long-term value.

Unlike the current CAR-T therapies that mainly focus on the treatment of hematological tumors, which have clear and fixed targets, and most of them concentrate on CD19 and BCMA. After several years of exploration, its technical pathways, production processes, and clinical applications...ApplicationIt has been relatively standardized. The technical path selection of TIL therapy makes it more focused on solid tumor cell treatment, plus...Limited Fixed TargetPoint, personalized characteristics and process complexity have raised the threshold for entering this track, thusCurrently, there are only a few companies globally that are focused on the development of TIL therapies, and only one TIL drug has been approved for market, indicating that large-scale market competition has yet to take shape.

To further elaborate, TILTherapy is more focused on solid tumor cell treatment,TrueThe real threshold does not lie in"The question is not whether we can make an effective product," but whether we can build a technical system that continuously outputs and iterates.

In this sense,TILIn the field of competition, "who gets to market first" is only the first step; more importantly, who can be the first to successfully complete the entire commercial closed loop from R&D and production to payment.

Conclusion

At a time when the capital for innovative drugs is tightening and technological routes are rapidly diverging,IPOIt is no longer a synonym for success. For Juncell Therapeutics, going public is more like a phased test — to verify whether its judgment on the "feasible implementation path" for solid tumor cell therapy holds true.

TILWhether it will become the next main focus of immunotherapy for solid tumors still requires time and critical clinical data to provide the final answer. What is certain, however, is thatWhen the industry begins to examine the safety, efficacy, accessibility, and affordability of cell therapy from a broader perspective, solid tumor cell therapy has already reached a new starting point.

And Juncell Therapeutics is an important example at this starting point.